4D Molecular Therapeutics FDMT Contract Liabilities
Contract Liabilities at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's contract liabilities?
- 4D Molecular Therapeutics (FDMT) reported contract liabilities of $2.13M in Q1 2026.
- How has 4D Molecular Therapeutics's contract liabilities changed year-over-year?
- 4D Molecular Therapeutics's contract liabilities increased by 389.6% year-over-year, from $434K to $2.13M.
- What is the long-term trend for 4D Molecular Therapeutics's contract liabilities?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's contract liabilities has grown at a -43.7% compound annual growth rate (CAGR), from $13.23M to $745K.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.